Thursday, July 3, 2025 7/3/2025

Mechanisms and protective efficacy of nanovaccines against Chlamydia trachomatis

Award Number: R21AI111159
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2014
PERIOD OF PERFORMANCE END DATE: 07/31/2018

Group Awards By:

View Award Description

Mechanisms and protective efficacy of nanovaccines against Chlamydia trachomatis - DESCRIPTION (provided by applicant): Chlamydia trachomatis is a sexually transmitted bacterium of public health concerns because it causes morbidity and socioeconomic burdens, such as infertility, ectopic pregnancy and chronic abdominal pain. Despite many years of vaccine development efforts, there is no vaccine against C. trachomatis, which probably stems in part from ineffective delivery systems or formulations that do not bolster immune responses to achieve long-lasting protective immunity. Therefore it is essential to explore other delivery systems that may effectively enhance the vaccine efficacy. Biodegradable nanoparticles offer attractive alternatives as adjuvants and delivery systems because they effectively enhance immunogenicity by providing controlled and sustained release of antigens to the immune system. We have developed two novel C. trachomatis nanovaccines employing PLGA (Poly D, L-lactic-co-glycolic acid) and PLA-PEG (Poly D, L-lactic acid-Polyethylene glycol), respectively as delivery systems for its recombinant major outer membrane protein (rMOMP) and peptide derivative (named M278). The named PLGA-rMOMP and PLA-PEG-M278 nanovaccines were immunogenic, immune-potentiating, and triggered profound C. trachomatis correlative Th1 protective immune responses in mice. Our goals are to investigate the molecular mechanisms by which nanovaccines interact with antigen presenting cells for T cell activation; the T and B cell-mediated effectors of the Th1 correlative protective immune responses, and whether the immune correlates can provide complete protective immunity against C. trachomatis infection in mice. Two specific aims are proposed to accomplish our goals. In SA1 we will assess the interaction of nanovaccines with antigen presenting cells for receptor-mediated recognition, cellular uptake, processing, and T cell subsets activation to produce Th1 protective immune responses. In SA2, we will immunize mice with nanovaccines to measure Th1 cellular and humoral protective immune correlates and evaluate whether these correlates can provide short- and long-term protective immunity against C. trachomatis infection in mice. Achieving this proposal's goals would positively impact C. trachomatis vaccine research and improve our efforts toward developing an anti-Chlamydia vaccine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = -$35,708 )
2019	2015	ALABAMA STATE UNIVERSITY	915 S JACKSON ST	MONTGOMERY	AL	36104	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	2/8/2019	NON-COMPETING CONTINUATION	-$35,708
														Subtotal = -$35,708

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2015	ALABAMA STATE UNIVERSITY	915 S JACKSON ST	MONTGOMERY	AL	36104	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	8/3/2017	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2015 ( Subtotal = $182,173 )
2015	2015	ALABAMA STATE UNIVERSITY	P.O. BOX 271	MONTGOMERY	AL	36101	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	7/9/2015	NON-COMPETING CONTINUATION	$182,173
														Subtotal = $182,173

Issue Date FY: 2014 ( Subtotal = $158,953 )
2014	2014	ALABAMA STATE UNIVERSITY	P.O. BOX 271	MONTGOMERY	AL	36101	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	1	7/29/2014	NEW	$158,953
														Subtotal = $158,953

Grand Total All Awards = $305,418

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mechanisms and protective efficacy of nanovaccines against Chlamydia trachomatis

Award Number: R21AI111159

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2014

PERIOD OF PERFORMANCE END DATE: 07/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer